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In a group of 96 children and teenagers suffering from absence epilepsy, we compared the 
efficacy of treatment with a valproic acid derivative, Depakin (D). In 72 patients of group 1, 
EEGs contained bursts of typical absence seizure phenomena, generalized 3–4 Hz spike/wave 
complexes, SWCs. In 24 patients of group 2, these EEG phenomena were combined with 
other types of epileptiform elements (generalized and focal irregular peak/wave complexes, 
single and grouped sharp waves, spikes, polyspikes, etc.). It was found that pharmacotherapy 
with D effectively eliminated SWCs generated in the resting state of the patients; epileptiform 
phenomena provoked by hyperventilation and rhythmic photostimulation were noticeably 
more resistant from this aspect. The efficacy of treatment with D was considerably higher 
in group 1 (patients with the EEG patterns including only SWCs) than in group 2 (patients 
with deviating EEG patterns containing, together with SWCs, epileptiform elements of other 
types). Six months after the D therapy initiation, complete elimination of typical 3-4 Hz 
SWCs was observed in 63.9% of group-1 patients and in 41.7% of group-2 patients. 
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INTRODUCTION 
According to the statements of the International 
League Against Epilepsy (ILAE) Commission on 
Classification and Terminology, absence epilepsy 
can be manifested in (i) typical or atypical absence 
seizures and (ii) seizures with special features [1]. 
Pathognomonic EEG correlates of typical absence 
seizures (TASs) look as generalized spike/slow wave 
complexes (SWCs, 3-4 Hz). In clinical practice, 
however, many deviating cases are encountered 
where the EEG pattern containing TASs is combined 
with other types of epileptiform phenomena, namely 
irregular peak/wave complexes, sharp waves, spikes, 
polyspikes, etc. [2-11]. 
According to the ILAE recommendations, a first-
line choice for the treatment of TASs is valproic acid 
and its derivatives [12]. The existence of absence 
epilepsy cases with dissimilar EEG patterns should, 
apparently, be taken into consideration when selecting 
an adequate strategy of treatment. In the accessible 
literature we, however, have not met publications 
devoted to the dynamics of combined EEG patterns at 
TASs during monotherapy with valproic acid and its 
derivatives. 
In this regard, it seemed expedient to carry out a 
comparative study of the dynamics of epileptiform 
discharges in patients suffering from absence 
epilepsy with typical and deviating EEG patterns 
under conditions of monotherapy with one of the 
valproic acid-based drugs, Depakin (D). The results 
of such study were assumed to be useful in selecting 
an adequate treatment strategy with respect to TASs 
characterized by different EEG patterns. It should 
be emphasized, that the term “typical absence,” or 
“TAS,” used within this context refers rather to the 
EEG pattern, than to the clinical (behavioral) type of 
epileptic seizures. 
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METHODS
In total, 96 patients with the clinical diagnosis of 
TAS, who were treated against absence epilepsy, were 
examined. These were 4- to 16-year-old children; they 
underwent routine EEG examination in the David 
Tatishvili Medical Center (Tbilisi, Georgia) within 
the period of 2005–2012. The main requirement of 
the selection consisted in that the patient had at least 
three consecutive registrations of EEG: at the first 
visit to the physician (prior to the treatment) and three 
and six months after the start of monotherapy with 
D. The dosage for each patient was standard, and the 
treatment was carried out under constant control of the 
drug level in the blood plasma.
The EEG examination in all patients was performed 
using standard techniques, in the morning against the 
background of quiet wakefulness. The patients were 
in a sound- and light-attenuated room, at a controlled 
ambient temperature of 22°C. The mean duration of 
EEG recording was 30-35 min.
The EEG signals were digitally recorded using an 
EEG analyzer, Encephalan 131-03 (Medicom MTD, 
Russia) and 19 scalp electrodes located according to 
the international 10–20 system with a linked ear contact 
as a reference. The amplifier bandpass was 0.5 to 
100 Hz, with a 50 Hz notch filter (outputs being 
3 db down at these frequencies). The signals from each 
electrode were digitized with the sampling rate 256 sec–1 
and resolution of 12 bits. The specific resistance of 
Ag/AgCl electrodes was between 5 and 1 kΩ. The EEG 
samples were stored on a hard disk for off-line analysis.
The EEG recording started with the eyes closed 
(5 min, background activity), continued with the 
eyes open (5 min), and once again with eyes closed 
(3 min). During EEG recording, standard activation 
procedures, namely rhythmic photic stimulation (RPS) 
and hyperventilation (HpV) were used. The former was 
carried out with the eyes closed, the flash lamp was 
positioned approximately 30 cm in front of the eyes. 
The procedure started with three flashes per second, 
and the frequency was gradually increased to the rate 
of 27 sec–1. Each flash rate was presented for about 
10 sec. The pV procedure lasted 3-5 min with the eyes 
open and closed, and with the breath hold (25-30 sec 
after HpV termination.
RESULTS
The entire examined contingent of 96 patients was 
divided into two groups (Table 1). Group 1 involved 
72 subjects (75% of the total number); in EEGs of these 
patients only SWC (3-4 Hz) bursts were observed. 
Group 2 included 24 patients (25% of the total number) 
who, along with 3-4 Hz SWCs, showed epileptiform 
elements of various morphology; these were focal or 
generalized single and grouped peak/wave complexes, 
sharp waves, EEG spikes, polyspikes, etc. 
Most patients of groups 1 and 2 (62.5 and 54.2%, 
respectively) were 4 to 8 years old. Much smaller 
proportions of the patients (12.5% in both groups) 
included teenagers (13 to 16 years). Girls prevailed 
in most above-mentioned age subgroups; three 13- to 
T a b l e 1. Characteristics of the studied sampling. 1 and 2) Groups of patients with a typical TAS EEG pattern containing 
exclusively SWCs (1) and those who, along with the TAS pattern demonstrated epileptiform phenomena of different morphologies (2, 
see the text); n is number of  patients; a and b are percentages in the total sampling and in the given group, respectively
Т а б л и ц я. 1. Характеристики обстеженої групи 
Contingent
Group
1 2
N a B N a b
4-8 years 45 46.9% 62.5% 13 13.5% 54.2%
M 14 14.6% 19.4% 4 4.2% 16.7%
F 31 32.3% 43.0% 9 9.4% 37.5%
9-12 years 18 18.7% 25.0% 8 8.3% 33.3%
M 7 7.3% 9.7% 3 3.1% 12.5%
F 11 11.5% 15.3% 5 5.2% 20.8%
13-6 years 9 9.4% 12.5% 3 3.1% 12.5%
M 3 3.1% 4.21% 2 2.1% 8.3%
F 6 6.2% 8.31% 1 1.1% 4.2%
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16-year-old patients of group 2 were two boys and one 
girl. 
Efficacy of Treatment in Group 1. The analysis of 
results of D-based treatment in group 1 is presented in 
Table 2. In this group, the greatest subgroup (51.4%) 
of TAS patients was characterized by the EEG pattern, 
with included generalized 3-4 Hz SWCs observed in 
both background state and after the action of HpV 
(subgroup A). In 31.9% of the cases, SWCs were 
absent in the resting state but could be provoked by 
HpV (subgroup B). In 9.7% of subjects of group 1, 
such bursts arose spontaneously and could be induced 
by both HpV and RPS procedures (subgroup C). In 
6.9% of group-1 patients, 3-4 Hz SWCs were not 
generated spontaneously, but could be induced by both 
Hpv and RPS (subgroup D). 
The analysis of EEGs, recorded three and six months 
after initiation of the treatment with D, showed that 
such treatment provided almost complete suppression 
of generation of spontaneous background SWC bursts 
in all above-mentioned subgroups.. The SWC bursts 
initiated by activation procedures were noticeably 
more resistant to the treatment used. In this regard, it 
should be emphasized that, after 3- and 6-month-long 
treatment, only 3-4 Hz SWCs provoked by activation 
procedures continued to be recorded (Table 2).
We also should note that clinical improvement (i.e., 
suppression of clinical seizure attacks) did not always 
coincide with EEG findings. In 11 patients of group 1 
(15.3%) with full elimination of clinical attacks, SWC 
bursts induced by activation procedures continued to 
be recorded in EEGs. 
Table 2 also illustrates the percentage of patients 
who demonstrated complete elimination of the SWCs 
in EEGs six months after initiation of the D treatment. 
In group 1 in general, the number of such successful 
cases made up 63.9%; this figure agrees with the data 
reported by other authors [12-14]. It seems that the best 
results (69.6%) were observed in patients of subgroup 
B (in which EEG SWC bursts arose only against HpV), 
but the difference from subgroup A in this respect is 
probably insignificant. Subgroup D, in which 3-4 Hz 
SWCs were not generated spontaneously but could 
be provoked by both HpV and RPS, demonstrated the 
greatest resistivity to the influence of D (the treatment 
was successful in only 40%). 
Efficacy of Treatment in Group 2. In patients 
of this group, EEG patterns contained both SWCs 
and epileptiform elements of differing morphology. 
Most frequently, SWC bursts were combined with 
focal epileptiform elements (19 cases, 79.2%), less 
frequently (5 cases, 20.8%), such elements were 
generalized (Fig. 1).
Deviating epileptiform elements were most 
frequently recorded in the fronto-central and fronto-
temporo-central sites (66%). In most cases, such 
epileptiform elements looked as irregular single 
or grouped spike/wave or sharp wave/slow wave 
complexes (18 patients, 75%). Less frequently, spike 
and polyspike discharges were observed (6 patients, 
25%). These elements occurred spontaneously in 
the background EEG, but more frequently they 
were provoked by HpV. In two patients, specific 
epileptiform discharges were provoked only by RPS, 
T a b l e 2. Dynamics of the EEG patterns in group 1. A-D) Subgroups of group 1; 1) before the treatment; 2 and 3) three and six 
months after the start of the treatment with Depakin. The last column shows the percentage of successful cases, revealed six months 
after initiation of the treatment (see the text)
Т а б л и ц я. 2. Динаміка змін патернів ЕЕГ у групі 1 
Subgroups
Registration
1 2 3 Positive effect (%)
A
Spontaneous and activated 
by HPV
37 (51.4%) 24 13 64.9%
B
Activated only by HPV
23 (31.9%) 16 7 69.6%
C
Activated by HPV and RPS
7 (9.7%) 5 3 57.1%
D
Spontaneous and activated 
by HPV and RPS
5 (6.9%) 3 3 40.0%
Total 72 48 26 63.9%
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Example of a combination of spike/wave complexes (SWCs, 3-4 Hz) with generalized epileptiform discharges provoked by activation 
procedures (before the start of the treatment). A) Typical absence SWCs provoked by hyperventilation; B) 
generalized epileptiform discharges provoked by repetitive photostimulation.
Приклад комбінації комплексів пік/хвиля (SWC, 3-4 Гц) з генералізованими епілептиформними розрядами, провокованими 
активаційними процедурами (перед початком лікування).
Fp2-F4
A
B
F4-C4
C4-P4
P4-O2
Fp2-F8
F8-T4
T4-T6
T6-O2
Fp1-F3
F3-C3
C3-P3
P3-O1
Fp1-F7
F7-T3
T3-T5
T5-O1
Fz-Cz
Cz-Pz
Fp-F4
F4-C4
C4-P4
P4-O2
Fp-F8
F8-F4
T4-T6
T6-O2
Fp1-F3
F3-C3
C3-P3
P3-O1
Fp1-F7
F7-T3
T3-T5
T5-O1
Fz-Cz
Oz-Pz
1 μV
1 sec
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and in two cases they were induced by both RPS and 
HpV (Table 3).
Similarly to what was observed in patients of group 
1, the D-based treatment was considered successful 
at complete elimination of epileptiform elements in 
EEG. In other words, the cases, where introduction of 
D eliminated generation of 3-4 Hz SWCs, but other 
types of epileptiform EEG elements continued to be 
generated, were not interpreted as successful.
The number of patients in subgroups of group 2 is 
limited; this is why we do not present the percentage 
of successful and unsuccessful cases for each subgroup 
separately. At the same time, it should be emphasized 
that,  in general,  the percentage of successful 
treatment cases six months after the beginning of 
pharmacotherapy with D was 41.7%, i.e., significantly 
smaller than the respective index in group 1.
Patients with deviating epileptiform discharges 
provoked by both RPS and HpV and accompanying 
SWCs appeared to be more resistant to the D treatment. 
It should be noted that intensification of concomitant 
deviating epileptiform discharges was observed in a 
parallel manner with complete elimination of SWCs 
in three patients of group 2. Suppression of SWC 
bursts under the influence of D in this group was 
noticeably slower than in patients of group 1. Three 
months after the start of treatment with D, bursts of 
SWCs continued to be recorded in 48 patients (65.3%) 
of group 1 and in 21 patients (87.5%) of group 2 
(Tables 1 and 2). 
DISCUSSION
The characteristics of group-1 patients (Table 1) are 
mostly compliant with the existing statistical data. In 
this group, the largest part (62.5%) was represented by 
4- to 8-year-old patients, i.е., their age was commonly 
viewed as a peak of TAS manifestations [15-18]. Age 
groups of 9-12 and 13-16 years made up 25% and 
12.5% of general sampling, respectively. Some doubts 
in respect to the manifestation of TAS in children elder 
than 10 years were expressed [15-18]. Other authors 
reported that absence epilepsy was diagnosed in 
10- to 15-year-old patients and those over 15 years 
in 17.8 and 2.8% of the cases, respectively [19]. 
Comparable results were presented by Hauser [20]. 
Granieri et al. [21] reported TASs could be observed 
T a b l e 3. Occurrence of EEG deviating epileptiform elements in patients of group 2 treated with Depakin. Other designations are 
similar to those in Table 2. Detailed explanations are presented in the text
Т а б л и ц я. 3. Наявність девіантних епілептиформних ЕЕГ-феноменів у пацієнтів групи 2, підданих лікуванню депакіном
SWCs (3–4 Hz) and
other epileptiform elements
Registration
1 2 3
A. Spontaneous   in  background   EEG
                 focal
                 generalized
3
1
3
1
2
0
B. Provoked by HPV  
               focal 
              generalized
5
1
4
1
2
1
C. Provoked by RPS 
                focal 
               generalized
1
1
1
1
1
1
D. Provoked by HPV+RPS  
               focal    
              generalized
2
0
2
0
2
0
E. Spontaneous + HPV 
               focal 
              generalized
7
2
5
2
3
1
F.  Spontaneous  + HPV + RPS
         focal  
           generalized
1
0
1
0
1
0
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rather frequently in 10-19-year-old patients and, 
sometimes, in 20- to 39-year-old subjects. Such 
discrepancies between the data of various authors can 
be accounted for differences in the diagnostic criteria 
used by different researchers [15-18, 22]. 
Gender distinctions in the patients of group 1 also 
corresponded to the conventional statistical data. TASs 
were more frequently encountered in girls than in boys 
making up 66.7 and 33.3%, respectively [15-19, 23-
25]. Interestingly, practically the same ratio between 
girls and boys was also observed in all selected age 
subgroups, namely 68.9 and 31.1% in the 4-8-year 
subgroup, 61.1 and 38.9% in the 9-12-year subgroup, 
and 66.7 and 33.3% in the 13-16-year subgroup.
In agreement with the existing literature data [23, 
26, 27], HpV provoked TASs in all patients of group 
1. In most cases (51.4%), the TAS EEG pattern was 
manifested as short (4-7 sec) spontaneous SWC bursts 
in the background EEG and as longer (6-12 sec) trains 
at the HpV action. In a part of cases (9.7%), 3-4 Hz 
SWCs were provoked not only by HpV but also by 
RPS. Probably, special attention should be paid to 
these cases because the ILAE Commission did not 
consider EEG reactions to RPS as an adequate EEG-
sign of TAS [15-18, 25, 28,]. Some authors admitted 
the possibility of high photosensitivity in TAS [26, 
29].
The absence of video monitoring of seizures is a 
noticeable drawback of our study. This procedure 
may allow us to reveal certain specificity of 
behavioral manifestations of the attacks developing 
in patients under HpV and RPS influences. Our study 
was exceptionally based on the analysis of EEG 
phenomena; nonetheless, we decided to include such 
patients in group 1 as a separate subgroup. 3-4 Hz 
SWCs induced by RPS met all criteria of the TAS 
EEG pattern and morphologically did not differ from 
the bursts provoked in the same patients by HpV. 
Considering the same grounds, we differentiated 
a small subgroup of patients (6.9%) in whom SWC 
bursts were recorded under all three conditions, in the 
resting state and during both RPS and HpV.
The highest  index of successfulness of D 
monotherapy (69.6%) was observed in patients with 
the EEG pattern of TAS recorded under background 
conditions and at HpV. This index was slightly lower 
(64.9%) in the cases where this pattern was also 
recorded as spontaneous bursts in the resting state. 
In the subgroup of patients with the SWC pattern 
provoked by both HpV and RPS the effectiveness of 
the therapy made up 57.1%. The lowest effectiveness 
of the treatment (40%) was observed in group 1 in the 
patients with the EEG pattern of TAS recorded both at 
rest and during HpV and RPS. 
The number of patients responding to RPS was rather 
limited; such reaction was observed in 12 patients 
(Table 2, subgroups D and E); the respective subgroups 
constituted 12.5% of group 1. It should be taken 
into account that HpV and RPS exert fundamentally 
different effects on the CNS; thus, it cannot be ruled 
out that high photosensitivity in these patients reflects 
certain specificity of the intimate mechanisms of 
epileptogenesis in such cases. The appearance of 
spontaneous and RPS- and HpV-provoked SWCs can 
apparently reflect a higher level of hyperexcitability 
in thalamic and/or cortical neuronal pools triggering 
this epileptiform EEG pattern. A high resistance of 
such patients to D monotherapy, as compared to that 
in patients from other subgroups, should surely be 
taken into consideration while choosing the strategy 
of anticonvulsive therapy in such patients.
Group 2. Cases where EEG of one and the same 
patient included 3-4 Hz SWCs and epileptiform 
phenomena of other types have been described by a 
few authors. The EEG pattern of TAS in a combination 
with single regional sharp wave/slow wave complexes 
was encountered in 1.5% of patients [4]. According 
to other authors [30], a typical absence EEG pattern 
with additional other generalized seizures and slow 
irregular spike-and-wave activity in the EEG was 
observed in 10.1% of cases. Epileptiform elements in 
TAS EEGs looking as centrotemporal sharp waves [25] 
or persistent focal disorders [7] were described by a 
number of authors [12].
In our study, the proportion of patients with the 
deviating combined EEG pattern was equal to 25% 
of the examined patient sampling. Probably, it is 
reasonable to emphasize that such a ratio cannot be 
considered completely adequately reflecting the real 
situation. The patients whose EEGs were analyzed, 
were selected according to certain special requirements 
(see Methods); therefore, the examined sampling 
cannot be regarded as statistically representative. 
In general, comparison of the findings made by the 
authors mentioned above suggests that the deviating 
combined EEG pattern containing SWCs and other 
generalized and/or focal epileptiform phenomena can 
be found in approximately 10% of subjects manifesting 
TASs.
As Table 3 shows, elimination of typical SVC bursts 
and concurrent varying epileptiform elements was 
observed after three and six months of D therapy in 
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10 out of 24 group-2 patients, i.e., in 41.7% of cases. 
Thus, the effect of such therapy in this group was much 
worse that in group 1 where it was 63.9% (Table 2). It 
should be again noted that such a low percentage of 
the treatment efficacy in group 1 was found only in 
patients with SWCs arising both spontaneously and 
provoked by RPS and HpV. 
Even more demonstrative is the fact related to the 
difference in the treatment efficacy observed three 
months after beginning of D introduction. Successful 
complete elimination of EEG paroxysms was observed 
in 24 patients of group 1 (33.3%), while in group 2, 
similar results were observed only in two patients 
(8.3%; Tables 2 and 3). 
The question on the existence of any pathogenetic 
relation between typical 3–4 Hz SWSs and other types 
of epileptiform discharges in EEG of the same patient 
remains unclear. In this connection, it is interesting 
that, in three patients of group 2, 3-4 Hz SWCs were 
completely suppressed, while other epileptyform 
phenomena of different types remained clearly 
manifested or even were intensified.
Of a special interest is the fact that the dynamics 
of D-provided elimination of TAS phenomena in 
EEGs three and six months after the start of treatment 
was markedly slower in patients of group 2 than 
in those of group 1. In other words, the patients 
of group 2 exhibited noticeably higher resistivity 
of typical SWC bursts to the action of D. Similar 
situation was described by Massa et al. [31] in 
patients with idiopathic Rolandic epilepsy. Possible 
neurophysiological background for this fact remains at 
present unclear. We can only state that a combination 
of the typical TAS pattern with other types of 
epileptiform phenomena in EEG of the same patients 
clearly correlates with a higher resistivity of seizures 
to the treatment with D. This situation, no doubt 
should be considered while planning the strategy of 
anticonvulsant therapy in such patients.
All participants were informed in detail about the experi-
mental process. The ethical protocol of this study was based on 
the Declaration of Helsinki and respective international ethical 
norms. The written informed consent was signed by all partici-
pants and/or their parents.
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Р е з ю м е
У групі з 96 дітей та підлітків, що страждали на абсансну 
епілепсію, ми порівнювали ефективність лікування з вико-
ристанням похідного вальпроєвої кислоти депакіну (Д). У 
72 пацієнтів групи 1 в ЕЕГ були присутні типові феномени 
абсансної судомної активності – генералізовані комплекси 
пік/хвиля (SWC, 3–4 Гц). У 24 пацієнтів такі ЕЕГ-феномени 
комбінувалися з епілептиформними елементами інших ти-
пів (генералізованими та фокальними нерегулярними комп-
лексами пік/хвиля, поодинокими та груповими гострими 
хвилями, ЕЕГ-піками, множинними піками і т. д.). Як ви-
явилося, фармакотерапія з використанням Д ефективно усу-
вала SWC, генеровані в спокійному стані пацієнтів; епілеп-
тиформні ЕЕГ-феномени, провоковані гіпервентиляцією та 
ритмічною фотостимуляцією, були помітно більш опірними 
в цьому аспекті. Ефективність лікування за допомогою Д  в 
групі 1 (пацієнти з наявністю виключно SWC у складі ЕЕГ) 
була істотно вищою, ніж у групі 2 (пацієнти з девіантними 
ЕЕГ-патернами, котрі містили в собі комбінації епілепти-
формних елементів інших типів із SWC). Через шість міся-
ців після початку прийому Д типові SWC (3–4 Гц) повністю 
зникали з ЕЕГ 63.9 % пацієнтів групи 1 та 41.7 % пацієн-
тів групи 2. 
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